Source 1review2021Frontiers in Cell and Developmental Biology
Toolkit/optogenetic zebrafish ALS model
optogenetic zebrafish ALS model
Also known as: disease-in-a-fish ALS model
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
The optogenetic zebrafish ALS model is an in vivo construct pattern in zebrafish in which light illumination is used to control oligomerization, phase transition, and aggregation of the ALS-associated DNA/RNA-binding protein TDP-43. It is presented as an optogenetic disease model for studying ALS-related TDP-43 protein state changes.
Usefulness & Problems
Why this is useful
This model is useful for probing ALS pathogenesis by enabling light-controlled manipulation of TDP-43 state changes in a living vertebrate system. Zebrafish larval transparency also allows non-invasive in vivo visualization of single spinal motor neurons from soma to neuromuscular synapse.
Source:
We then introduce a recently developed optogenetic zebrafish ALS model that uses light illumination to control oligomerization, phase transition and aggregation of the ALS-associated DNA/RNA-binding protein called TDP-43.
Problem solved
It addresses the problem of studying how TDP-43 oligomerization, phase transition, and aggregation contribute to ALS in vivo. The cited review discusses this disease-in-a-fish approach as a way to help answer key questions about ALS pathogenesis and support development of new ALS therapeutics.
Problem links
Need precise spatiotemporal control with light input
DerivedThe optogenetic zebrafish ALS model is a disease-in-a-fish construct pattern in which light illumination is used to control oligomerization, phase transition, and aggregation of the ALS-associated DNA/RNA-binding protein TDP-43 in zebrafish. It is presented as an optogenetic in vivo model for studying ALS-related TDP-43 protein state changes.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
light-controlled oligomerizationlight-controlled oligomerizationOligomerizationphase transitionphase transitionprotein aggregationprotein aggregationTechniques
No technique tags yet.
Target processes
No target processes tagged yet.
Input: Light
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationimplementation constraint: spectral hardware requirementoperating role: actuator
The available evidence indicates that the model is implemented in zebrafish and actuated by light illumination to control TDP-43 behavior. Specific construct architecture, photoreceptor module, promoter choice, expression strategy, and wavelength requirements are not provided in the supplied evidence.
The supplied evidence does not report quantitative performance, illumination parameters, reversibility, temporal resolution, or phenotypic outcomes. Independent replication and breadth of validation are also not established from the provided sources.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Larval zebrafish transparency allows non-invasive in vivo visualization of single spinal motor neurons from soma to neuromuscular synapse.
Larval zebrafish have transparent bodies that allow non-invasive visualization of whole cells of single spinal motor neurons, from somas to the neuromuscular synapses.
Larval zebrafish transparency allows non-invasive in vivo visualization of single spinal motor neurons from soma to neuromuscular synapse.
Larval zebrafish have transparent bodies that allow non-invasive visualization of whole cells of single spinal motor neurons, from somas to the neuromuscular synapses.
Larval zebrafish transparency allows non-invasive in vivo visualization of single spinal motor neurons from soma to neuromuscular synapse.
Larval zebrafish have transparent bodies that allow non-invasive visualization of whole cells of single spinal motor neurons, from somas to the neuromuscular synapses.
Larval zebrafish transparency allows non-invasive in vivo visualization of single spinal motor neurons from soma to neuromuscular synapse.
Larval zebrafish have transparent bodies that allow non-invasive visualization of whole cells of single spinal motor neurons, from somas to the neuromuscular synapses.
Larval zebrafish transparency allows non-invasive in vivo visualization of single spinal motor neurons from soma to neuromuscular synapse.
Larval zebrafish have transparent bodies that allow non-invasive visualization of whole cells of single spinal motor neurons, from somas to the neuromuscular synapses.
Larval zebrafish transparency allows non-invasive in vivo visualization of single spinal motor neurons from soma to neuromuscular synapse.
Larval zebrafish have transparent bodies that allow non-invasive visualization of whole cells of single spinal motor neurons, from somas to the neuromuscular synapses.
Larval zebrafish transparency allows non-invasive in vivo visualization of single spinal motor neurons from soma to neuromuscular synapse.
Larval zebrafish have transparent bodies that allow non-invasive visualization of whole cells of single spinal motor neurons, from somas to the neuromuscular synapses.
Larval zebrafish transparency allows non-invasive in vivo visualization of single spinal motor neurons from soma to neuromuscular synapse.
Larval zebrafish have transparent bodies that allow non-invasive visualization of whole cells of single spinal motor neurons, from somas to the neuromuscular synapses.
Larval zebrafish transparency allows non-invasive in vivo visualization of single spinal motor neurons from soma to neuromuscular synapse.
Larval zebrafish have transparent bodies that allow non-invasive visualization of whole cells of single spinal motor neurons, from somas to the neuromuscular synapses.
Larval zebrafish transparency allows non-invasive in vivo visualization of single spinal motor neurons from soma to neuromuscular synapse.
Larval zebrafish have transparent bodies that allow non-invasive visualization of whole cells of single spinal motor neurons, from somas to the neuromuscular synapses.
Larval zebrafish transparency allows non-invasive in vivo visualization of single spinal motor neurons from soma to neuromuscular synapse.
Larval zebrafish have transparent bodies that allow non-invasive visualization of whole cells of single spinal motor neurons, from somas to the neuromuscular synapses.
Larval zebrafish transparency allows non-invasive in vivo visualization of single spinal motor neurons from soma to neuromuscular synapse.
Larval zebrafish have transparent bodies that allow non-invasive visualization of whole cells of single spinal motor neurons, from somas to the neuromuscular synapses.
Larval zebrafish transparency allows non-invasive in vivo visualization of single spinal motor neurons from soma to neuromuscular synapse.
Larval zebrafish have transparent bodies that allow non-invasive visualization of whole cells of single spinal motor neurons, from somas to the neuromuscular synapses.
Larval zebrafish transparency allows non-invasive in vivo visualization of single spinal motor neurons from soma to neuromuscular synapse.
Larval zebrafish have transparent bodies that allow non-invasive visualization of whole cells of single spinal motor neurons, from somas to the neuromuscular synapses.
Larval zebrafish transparency allows non-invasive in vivo visualization of single spinal motor neurons from soma to neuromuscular synapse.
Larval zebrafish have transparent bodies that allow non-invasive visualization of whole cells of single spinal motor neurons, from somas to the neuromuscular synapses.
Larval zebrafish transparency allows non-invasive in vivo visualization of single spinal motor neurons from soma to neuromuscular synapse.
Larval zebrafish have transparent bodies that allow non-invasive visualization of whole cells of single spinal motor neurons, from somas to the neuromuscular synapses.
Larval zebrafish transparency allows non-invasive in vivo visualization of single spinal motor neurons from soma to neuromuscular synapse.
Larval zebrafish have transparent bodies that allow non-invasive visualization of whole cells of single spinal motor neurons, from somas to the neuromuscular synapses.
Larval zebrafish transparency allows non-invasive in vivo visualization of single spinal motor neurons from soma to neuromuscular synapse.
Larval zebrafish have transparent bodies that allow non-invasive visualization of whole cells of single spinal motor neurons, from somas to the neuromuscular synapses.
Larval zebrafish transparency allows non-invasive in vivo visualization of single spinal motor neurons from soma to neuromuscular synapse.
Larval zebrafish have transparent bodies that allow non-invasive visualization of whole cells of single spinal motor neurons, from somas to the neuromuscular synapses.
Larval zebrafish transparency allows non-invasive in vivo visualization of single spinal motor neurons from soma to neuromuscular synapse.
Larval zebrafish have transparent bodies that allow non-invasive visualization of whole cells of single spinal motor neurons, from somas to the neuromuscular synapses.
Larval zebrafish transparency allows non-invasive in vivo visualization of single spinal motor neurons from soma to neuromuscular synapse.
Larval zebrafish have transparent bodies that allow non-invasive visualization of whole cells of single spinal motor neurons, from somas to the neuromuscular synapses.
Larval zebrafish transparency allows non-invasive in vivo visualization of single spinal motor neurons from soma to neuromuscular synapse.
Larval zebrafish have transparent bodies that allow non-invasive visualization of whole cells of single spinal motor neurons, from somas to the neuromuscular synapses.
Larval zebrafish transparency allows non-invasive in vivo visualization of single spinal motor neurons from soma to neuromuscular synapse.
Larval zebrafish have transparent bodies that allow non-invasive visualization of whole cells of single spinal motor neurons, from somas to the neuromuscular synapses.
Larval zebrafish transparency allows non-invasive in vivo visualization of single spinal motor neurons from soma to neuromuscular synapse.
Larval zebrafish have transparent bodies that allow non-invasive visualization of whole cells of single spinal motor neurons, from somas to the neuromuscular synapses.
Larval zebrafish transparency allows non-invasive in vivo visualization of single spinal motor neurons from soma to neuromuscular synapse.
Larval zebrafish have transparent bodies that allow non-invasive visualization of whole cells of single spinal motor neurons, from somas to the neuromuscular synapses.
Larval zebrafish transparency allows non-invasive in vivo visualization of single spinal motor neurons from soma to neuromuscular synapse.
Larval zebrafish have transparent bodies that allow non-invasive visualization of whole cells of single spinal motor neurons, from somas to the neuromuscular synapses.
Larval zebrafish transparency allows non-invasive in vivo visualization of single spinal motor neurons from soma to neuromuscular synapse.
Larval zebrafish have transparent bodies that allow non-invasive visualization of whole cells of single spinal motor neurons, from somas to the neuromuscular synapses.
The disease-in-a-fish ALS model is discussed as a way to help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
Finally, we will discuss how this disease-in-a-fish ALS model can help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
The disease-in-a-fish ALS model is discussed as a way to help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
Finally, we will discuss how this disease-in-a-fish ALS model can help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
The disease-in-a-fish ALS model is discussed as a way to help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
Finally, we will discuss how this disease-in-a-fish ALS model can help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
The disease-in-a-fish ALS model is discussed as a way to help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
Finally, we will discuss how this disease-in-a-fish ALS model can help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
The disease-in-a-fish ALS model is discussed as a way to help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
Finally, we will discuss how this disease-in-a-fish ALS model can help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
The disease-in-a-fish ALS model is discussed as a way to help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
Finally, we will discuss how this disease-in-a-fish ALS model can help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
The disease-in-a-fish ALS model is discussed as a way to help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
Finally, we will discuss how this disease-in-a-fish ALS model can help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
The disease-in-a-fish ALS model is discussed as a way to help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
Finally, we will discuss how this disease-in-a-fish ALS model can help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
The disease-in-a-fish ALS model is discussed as a way to help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
Finally, we will discuss how this disease-in-a-fish ALS model can help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
The disease-in-a-fish ALS model is discussed as a way to help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
Finally, we will discuss how this disease-in-a-fish ALS model can help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
The disease-in-a-fish ALS model is discussed as a way to help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
Finally, we will discuss how this disease-in-a-fish ALS model can help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
The disease-in-a-fish ALS model is discussed as a way to help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
Finally, we will discuss how this disease-in-a-fish ALS model can help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
The disease-in-a-fish ALS model is discussed as a way to help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
Finally, we will discuss how this disease-in-a-fish ALS model can help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
The disease-in-a-fish ALS model is discussed as a way to help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
Finally, we will discuss how this disease-in-a-fish ALS model can help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
The disease-in-a-fish ALS model is discussed as a way to help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
Finally, we will discuss how this disease-in-a-fish ALS model can help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
The disease-in-a-fish ALS model is discussed as a way to help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
Finally, we will discuss how this disease-in-a-fish ALS model can help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
The disease-in-a-fish ALS model is discussed as a way to help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
Finally, we will discuss how this disease-in-a-fish ALS model can help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
The disease-in-a-fish ALS model is discussed as a way to help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
Finally, we will discuss how this disease-in-a-fish ALS model can help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
The disease-in-a-fish ALS model is discussed as a way to help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
Finally, we will discuss how this disease-in-a-fish ALS model can help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
The disease-in-a-fish ALS model is discussed as a way to help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
Finally, we will discuss how this disease-in-a-fish ALS model can help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
The disease-in-a-fish ALS model is discussed as a way to help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
Finally, we will discuss how this disease-in-a-fish ALS model can help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
The disease-in-a-fish ALS model is discussed as a way to help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
Finally, we will discuss how this disease-in-a-fish ALS model can help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
The disease-in-a-fish ALS model is discussed as a way to help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
Finally, we will discuss how this disease-in-a-fish ALS model can help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
The disease-in-a-fish ALS model is discussed as a way to help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
Finally, we will discuss how this disease-in-a-fish ALS model can help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
The disease-in-a-fish ALS model is discussed as a way to help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
Finally, we will discuss how this disease-in-a-fish ALS model can help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
The disease-in-a-fish ALS model is discussed as a way to help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
Finally, we will discuss how this disease-in-a-fish ALS model can help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
The disease-in-a-fish ALS model is discussed as a way to help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
Finally, we will discuss how this disease-in-a-fish ALS model can help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
A recently developed optogenetic zebrafish ALS model uses light illumination to control TDP-43 oligomerization, phase transition, and aggregation.
We then introduce a recently developed optogenetic zebrafish ALS model that uses light illumination to control oligomerization, phase transition and aggregation of the ALS-associated DNA/RNA-binding protein called TDP-43.
A recently developed optogenetic zebrafish ALS model uses light illumination to control TDP-43 oligomerization, phase transition, and aggregation.
We then introduce a recently developed optogenetic zebrafish ALS model that uses light illumination to control oligomerization, phase transition and aggregation of the ALS-associated DNA/RNA-binding protein called TDP-43.
A recently developed optogenetic zebrafish ALS model uses light illumination to control TDP-43 oligomerization, phase transition, and aggregation.
We then introduce a recently developed optogenetic zebrafish ALS model that uses light illumination to control oligomerization, phase transition and aggregation of the ALS-associated DNA/RNA-binding protein called TDP-43.
A recently developed optogenetic zebrafish ALS model uses light illumination to control TDP-43 oligomerization, phase transition, and aggregation.
We then introduce a recently developed optogenetic zebrafish ALS model that uses light illumination to control oligomerization, phase transition and aggregation of the ALS-associated DNA/RNA-binding protein called TDP-43.
A recently developed optogenetic zebrafish ALS model uses light illumination to control TDP-43 oligomerization, phase transition, and aggregation.
We then introduce a recently developed optogenetic zebrafish ALS model that uses light illumination to control oligomerization, phase transition and aggregation of the ALS-associated DNA/RNA-binding protein called TDP-43.
A recently developed optogenetic zebrafish ALS model uses light illumination to control TDP-43 oligomerization, phase transition, and aggregation.
We then introduce a recently developed optogenetic zebrafish ALS model that uses light illumination to control oligomerization, phase transition and aggregation of the ALS-associated DNA/RNA-binding protein called TDP-43.
A recently developed optogenetic zebrafish ALS model uses light illumination to control TDP-43 oligomerization, phase transition, and aggregation.
We then introduce a recently developed optogenetic zebrafish ALS model that uses light illumination to control oligomerization, phase transition and aggregation of the ALS-associated DNA/RNA-binding protein called TDP-43.
A recently developed optogenetic zebrafish ALS model uses light illumination to control TDP-43 oligomerization, phase transition, and aggregation.
We then introduce a recently developed optogenetic zebrafish ALS model that uses light illumination to control oligomerization, phase transition and aggregation of the ALS-associated DNA/RNA-binding protein called TDP-43.
A recently developed optogenetic zebrafish ALS model uses light illumination to control TDP-43 oligomerization, phase transition, and aggregation.
We then introduce a recently developed optogenetic zebrafish ALS model that uses light illumination to control oligomerization, phase transition and aggregation of the ALS-associated DNA/RNA-binding protein called TDP-43.
A recently developed optogenetic zebrafish ALS model uses light illumination to control TDP-43 oligomerization, phase transition, and aggregation.
We then introduce a recently developed optogenetic zebrafish ALS model that uses light illumination to control oligomerization, phase transition and aggregation of the ALS-associated DNA/RNA-binding protein called TDP-43.
A recently developed optogenetic zebrafish ALS model uses light illumination to control TDP-43 oligomerization, phase transition, and aggregation.
We then introduce a recently developed optogenetic zebrafish ALS model that uses light illumination to control oligomerization, phase transition and aggregation of the ALS-associated DNA/RNA-binding protein called TDP-43.
A recently developed optogenetic zebrafish ALS model uses light illumination to control TDP-43 oligomerization, phase transition, and aggregation.
We then introduce a recently developed optogenetic zebrafish ALS model that uses light illumination to control oligomerization, phase transition and aggregation of the ALS-associated DNA/RNA-binding protein called TDP-43.
A recently developed optogenetic zebrafish ALS model uses light illumination to control TDP-43 oligomerization, phase transition, and aggregation.
We then introduce a recently developed optogenetic zebrafish ALS model that uses light illumination to control oligomerization, phase transition and aggregation of the ALS-associated DNA/RNA-binding protein called TDP-43.
A recently developed optogenetic zebrafish ALS model uses light illumination to control TDP-43 oligomerization, phase transition, and aggregation.
We then introduce a recently developed optogenetic zebrafish ALS model that uses light illumination to control oligomerization, phase transition and aggregation of the ALS-associated DNA/RNA-binding protein called TDP-43.
A recently developed optogenetic zebrafish ALS model uses light illumination to control TDP-43 oligomerization, phase transition, and aggregation.
We then introduce a recently developed optogenetic zebrafish ALS model that uses light illumination to control oligomerization, phase transition and aggregation of the ALS-associated DNA/RNA-binding protein called TDP-43.
A recently developed optogenetic zebrafish ALS model uses light illumination to control TDP-43 oligomerization, phase transition, and aggregation.
We then introduce a recently developed optogenetic zebrafish ALS model that uses light illumination to control oligomerization, phase transition and aggregation of the ALS-associated DNA/RNA-binding protein called TDP-43.
A recently developed optogenetic zebrafish ALS model uses light illumination to control TDP-43 oligomerization, phase transition, and aggregation.
We then introduce a recently developed optogenetic zebrafish ALS model that uses light illumination to control oligomerization, phase transition and aggregation of the ALS-associated DNA/RNA-binding protein called TDP-43.
A recently developed optogenetic zebrafish ALS model uses light illumination to control TDP-43 oligomerization, phase transition, and aggregation.
We then introduce a recently developed optogenetic zebrafish ALS model that uses light illumination to control oligomerization, phase transition and aggregation of the ALS-associated DNA/RNA-binding protein called TDP-43.
A recently developed optogenetic zebrafish ALS model uses light illumination to control TDP-43 oligomerization, phase transition, and aggregation.
We then introduce a recently developed optogenetic zebrafish ALS model that uses light illumination to control oligomerization, phase transition and aggregation of the ALS-associated DNA/RNA-binding protein called TDP-43.
A recently developed optogenetic zebrafish ALS model uses light illumination to control TDP-43 oligomerization, phase transition, and aggregation.
We then introduce a recently developed optogenetic zebrafish ALS model that uses light illumination to control oligomerization, phase transition and aggregation of the ALS-associated DNA/RNA-binding protein called TDP-43.
A recently developed optogenetic zebrafish ALS model uses light illumination to control TDP-43 oligomerization, phase transition, and aggregation.
We then introduce a recently developed optogenetic zebrafish ALS model that uses light illumination to control oligomerization, phase transition and aggregation of the ALS-associated DNA/RNA-binding protein called TDP-43.
A recently developed optogenetic zebrafish ALS model uses light illumination to control TDP-43 oligomerization, phase transition, and aggregation.
We then introduce a recently developed optogenetic zebrafish ALS model that uses light illumination to control oligomerization, phase transition and aggregation of the ALS-associated DNA/RNA-binding protein called TDP-43.
A recently developed optogenetic zebrafish ALS model uses light illumination to control TDP-43 oligomerization, phase transition, and aggregation.
We then introduce a recently developed optogenetic zebrafish ALS model that uses light illumination to control oligomerization, phase transition and aggregation of the ALS-associated DNA/RNA-binding protein called TDP-43.
A recently developed optogenetic zebrafish ALS model uses light illumination to control TDP-43 oligomerization, phase transition, and aggregation.
We then introduce a recently developed optogenetic zebrafish ALS model that uses light illumination to control oligomerization, phase transition and aggregation of the ALS-associated DNA/RNA-binding protein called TDP-43.
A recently developed optogenetic zebrafish ALS model uses light illumination to control TDP-43 oligomerization, phase transition, and aggregation.
We then introduce a recently developed optogenetic zebrafish ALS model that uses light illumination to control oligomerization, phase transition and aggregation of the ALS-associated DNA/RNA-binding protein called TDP-43.
A recently developed optogenetic zebrafish ALS model uses light illumination to control TDP-43 oligomerization, phase transition, and aggregation.
We then introduce a recently developed optogenetic zebrafish ALS model that uses light illumination to control oligomerization, phase transition and aggregation of the ALS-associated DNA/RNA-binding protein called TDP-43.
A recently developed optogenetic zebrafish ALS model uses light illumination to control TDP-43 oligomerization, phase transition, and aggregation.
We then introduce a recently developed optogenetic zebrafish ALS model that uses light illumination to control oligomerization, phase transition and aggregation of the ALS-associated DNA/RNA-binding protein called TDP-43.
Approval Evidence
1 source3 linked approval claimsfirst-pass slug optogenetic-zebrafish-als-model
We then introduce a recently developed optogenetic zebrafish ALS model that uses light illumination to control oligomerization, phase transition and aggregation of the ALS-associated DNA/RNA-binding protein called TDP-43.
Source:
model system capabilitysupports
Larval zebrafish transparency allows non-invasive in vivo visualization of single spinal motor neurons from soma to neuromuscular synapse.
Larval zebrafish have transparent bodies that allow non-invasive visualization of whole cells of single spinal motor neurons, from somas to the neuromuscular synapses.
Source:
research utilitysupports
The disease-in-a-fish ALS model is discussed as a way to help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
Finally, we will discuss how this disease-in-a-fish ALS model can help solve key questions about ALS pathogenesis and lead to new ALS therapeutics.
Source:
tool functionsupports
A recently developed optogenetic zebrafish ALS model uses light illumination to control TDP-43 oligomerization, phase transition, and aggregation.
We then introduce a recently developed optogenetic zebrafish ALS model that uses light illumination to control oligomerization, phase transition and aggregation of the ALS-associated DNA/RNA-binding protein called TDP-43.
Source:
Comparisons
Source-backed strengths
A key strength is optical control over multiple TDP-43 state transitions, specifically oligomerization, phase transition, and aggregation, within zebrafish. Another strength is the zebrafish larval system itself, which permits non-invasive visualization of single spinal motor neurons across their full extent.
Compared with alkynyl-functionalized photocleavable linker
optogenetic zebrafish ALS model and alkynyl-functionalized photocleavable linker address a similar problem space.
Shared frame: same top-level item type; same primary input modality: light
Compared with optogenetic Amyloid-b2 peptide
optogenetic zebrafish ALS model and optogenetic Amyloid-b2 peptide address a similar problem space.
Shared frame: same top-level item type; shared mechanisms: oligomerization; same primary input modality: light
Compared with red light-inducible recombinase library
optogenetic zebrafish ALS model and red light-inducible recombinase library address a similar problem space.
Shared frame: same top-level item type; same primary input modality: light
Ranked Citations
- 1.